利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.045 秒)

    Remedy for diseases associated with immunoglobulin gene translocation
    8.
    发明申请
    Remedy for diseases associated with immunoglobulin gene translocation 审中-公开
    与免疫球蛋白基因易位相关疾病的补救措施

    公开(公告)号：US20070004674A1

    公开(公告)日：2007-01-04

    申请号：US10569090

    申请日：2004-08-23

    申请人： Yukimasa Shiotsu ,  Shiro Soga ,  Yutaka Kanda ,  Shiro Akinaga

    发明人： Yukimasa Shiotsu ,  Shiro Soga ,  Yutaka Kanda ,  Shiro Akinaga

    IPC分类号： A61K31/695 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/452 ,  A61K31/4433 ,  A61K31/4025 ,  A61K31/365

    CPC分类号： A61K31/365 ,  A61K31/00 ,  C07D313/00

    摘要： A medicament comprising a compound having an inhibitory action on Hsp90 or a pharmaceutically acceptable salt thereof as an active ingredient is used as a therapeutic agent for diseases associated with immunoglobulin gene translocations. In diseases associated with immunoglobulin gene translocations, abnormal enhancement of the expression of a partner gene in immunoglobulin gene translocation participates in the development of the diseases and the progress of the symptoms. By administering the compound having an inhibitory action on Hsp90 or a pharmaceutically acceptable salt thereof, degradation of protein encoded by the partner gene is promoted and the diseases can be treated.

    摘要翻译： 将包含对Hsp90或其药学上可接受的盐具有抑制作用的化合物作为活性成分的药物用作与免疫球蛋白基因易位相关的疾病的治疗剂。 在与免疫球蛋白基因易位相关的疾病中，免疫球蛋白基因易位中伴侣基因表达的异常增强参与疾病的发展和症状的进展。 通过施用对Hsp90具有抑制作用的化合物或其药学上可接受的盐，促进由配对基因编码的蛋白质的降解，并且可以治疗疾病。

    PHARMACEUTICAL COMPOSITION
    9.
    发明申请
    PHARMACEUTICAL COMPOSITION 审中-公开
    药物组合物

    公开(公告)号：US20100098690A1

    公开(公告)日：2010-04-22

    申请号：US12529380

    申请日：2008-03-05

    申请人： Shiro Soga ,  Toshihiko Ishii ,  Takayuki Nakashima ,  Yukimasa Shiotsu ,  Shiro Akinaga

    发明人： Shiro Soga ,  Toshihiko Ishii ,  Takayuki Nakashima ,  Yukimasa Shiotsu ,  Shiro Akinaga

    IPC分类号： A61K31/122 ,  A61K31/216 ,  A61K31/135 ,  A61K31/495 ,  A61K31/445 ,  A61K31/47 ,  A61K31/5375 ,  A61K31/44 ,  A61K31/075 ,  A61K31/165 ,  A61K31/05 ,  A61K31/5377 ,  A61K39/395 ,  A61K31/4965 ,  A61P35/00

    CPC分类号： A61K31/5375 ,  A61K31/198 ,  A61K31/337 ,  A61K31/5377 ,  A61K39/39558 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides a pharmaceutical composition comprising a combination of an Hsp 90 family protein inhibitor and at least one compound, the said pharmaceutical composition wherein the Hsp 90 family protein inhibitor is a benozoyl compound represented by formula (I): [wherein n represents an integer of 1 to 5; R1 represents substituted or unsubstituted lower alkyl, CONR7R8 (wherein R7 and R8, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like; R2 represents substituted or unsubstituted aryl, or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R4 represents a hydrogen atom, hydroxy or halogen; and R6 represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like], or a prodrug thereof; or a pharmaceutically acceptable salt thereof, and the like.

    摘要翻译： 本发明提供了包含Hsp90家族蛋白抑制剂和至少一种化合物的组合的药物组合物，所述药物组合物，其中Hsp 90家族蛋白抑制剂是由式（I）表示的新戊酰化合物：[其中n表示 1〜5的整数; R1表示取代或未取代的低级烷基CONR7R8（其中R7和R8可相同或不同，各自表示氢原子，取代或未取代的低级烷基等）等; R2表示取代或未取代的芳基等; R 3和R 5可以相同或不同，各自表示氢原子，取代或未取代的低级烷基等; R4表示氢原子，羟基或卤素; R6代表氢原子，卤素，取代或未取代的低级烷基等]或其前药; 或其药学上可接受的盐等。

    Radicicol derivatives
    10.
    发明授权
    Radicicol derivatives 失效
    蓝霉素衍生物

    公开(公告)号：US06635662B2

    公开(公告)日：2003-10-21

    申请号：US09791602

    申请日：2001-02-26

    申请人： Yoji Ino ,  Nobuyoshi Amishiro ,  Mayumi Miyata ,  Chikara Murakata ,  Harumi Ogawa ,  Tadakazu Akiyama ,  Shiro Akinaga ,  Shiro Soga ,  Yukimasa Shiotsu

    发明人： Yoji Ino ,  Nobuyoshi Amishiro ,  Mayumi Miyata ,  Chikara Murakata ,  Harumi Ogawa ,  Tadakazu Akiyama ,  Shiro Akinaga ,  Shiro Soga ,  Yukimasa Shiotsu

    IPC分类号： A61K3144

    CPC分类号： C07D493/04 ,  C07D313/00

    摘要： Radicicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof: wherein R1 and R2 are the same or different, and each represents hydrogen, alkanoyl, alkenoyl, tert-butyldiphenylsilyl or tert-butyldimethylsilyl; R3 represents Y—R5 {wherein Y represents substituted or unsubstituted alkylene; and R5 represents CONR5R7 (wherein R6 represents hydrogen, hydroxyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted higher alkyl, and the like; R7 represents hydroxyl, substituted lower alkyl, and the like), CO2R12 (wherein R12 represents substituted lower alkyl, substituted or unsubstituted higher alkyl, and the like), and the like} and the like; X represents halogen or is combined together with R4 to represent a single bond; and R4 is combined together with X to represent a single bond, or represents hydrogen, alkanoyl, and the like.

    摘要翻译： 由下式（I）表示的具有酪氨酸激酶抑制活性的衍生物衍生物或其药理学上可接受的盐：其中R 1和R 2相同或不同，各自表示氢，链烷酰基，烯酰基，叔丁基二苯基甲硅烷基或 叔丁基二甲基甲硅烷基; R 3表示Y-R 5 {其中Y表示取代或未取代的亚烷基; 并且R 5表示CONR 5 R 7（其中R 6表示氢，羟基，取代或未取代的低级烷基，取代或未取代的高级烷基等; R 7表示羟基，取代的低级 烷基等），CO 2 R 12（其中R 12表示取代的低级烷基，取代或未取代的高级烷基等）等}等; X表示卤素或与R 4结合以表示单键;并且R 4与X一起组合以表示单键，或表示氢，烷酰基等。